(0) Boehringer Ingelheim significantly expands its supply center for China
14 December 2011 - The goal of this project is to bring more health to more patients and to continuously improve Boehringer Ingelheim’s product competitiveness and enlarge its market share.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/14_december_2011centerforchina.html

(0) Cosmo announces FDA submission of new drug Application for uceris™ (budesonide) tablets by its Licensee santarus
Lainate (December 21, 2011) – Cosmo announced that its licensee Santarus, Inc., has submitted a New Drug Application (NDA) to the FDA seeking market approval for UCERIS™ (budesonide) Tablets 9 mg.
http://www.cosmopharmaceuticals.com/news/press/pr2011/21-12-11.aspx

(0) Etubics Ad5 Platform Overcomes Ad5 Immunity in Multiple Studies
December 21, 2011 – Clinical & Cellular Immunology Review Shows Company Can Break Ad5 Immunity Tolerance.
http://www.etubics.com/news/Press%20Release-Platform%20Overcomes%20Ad5%20Immunity.pdf

(0) FDA approves mechanical cardiac assist device for children with heart failure
Dec. 16, 2011: FDA today approved a medical device that supports the weakened heart of children with heart failure to help keep them alive until a donor for a heart transplant can be found.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm283956.htm

(0) Linagliptin demonstrates meaningful improvement in glycaemic control in initial combination therapy with metformin
8 December 2011 - Boehringer Ingelheim and Eli Lilly today announced results of a 24-week open label arm of a phase III study for linagliptin in initial combination with metformin.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/08_december_2011linagliptin.html

(0) Performance Qualification of a New Hyperomellose Capsule Part I and II Now Available
Dec. 12, 2011 - The results show the new capsule is superior in terms of mechanical strength, hygroscopicity and compatibility with a wide range of drugs.
http://capsugel.com/en/news-events/news/performance-qualification-of-a-new-hyperomellose-capsule-part-i-and-ii-now-available/

(0) ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze with Hyaluronidase
Complete data are expected to be presented at a future international scientific meeting.
http://www.halozyme.com/Investors/News-Releases/News-Release-Details/2011/ViroPharma-and-Halozyme-Therapeutics-Announce-Positive-Data-From-Initial-Phase-2-Assessment-of-Subcutaneous-Cinryze-C1-este/default.aspx

(0) Voraxaze® (glucarpidase) licensed to Ohara Pharmaceuticals in Japan
Under the terms of the license agreement BTG will also supply glucarpidase to Ohara. Ohara will be responsible for the development programme and registration in Japan.
http://www.btgplc.com/page/15917/media/press-releases/2011/btg-plc-voraxaze174-glucarpidase-licensed-to-ohara-pharmaceuticals-in-japan

(0) YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011
Dec. 12, 2011 - The results are being presented this evening in a poster session at the 53rd Annual Meeting of the American Society of Hematology underway in San Diego, CA.
http://www.ymbiosciences.com/investors/press_releases_item.php?newsid=1638865

(4) BASF increases prices for pharmaceutical excipients and active ingredients
Effective September 1, 2011, BASF will increase the sales prices globally for all pharmaceutical excipients and generic active pharmaceutical ingredients by 10%.
http://www.basf.com/group/pressrelease/P-11-392

1

2

3

4

5

6

7

8

9

Siguiente